| Literature DB >> 28249163 |
Kevin O Saunders1, Nathan I Nicely2, Kevin Wiehe2, Mattia Bonsignori2, R Ryan Meyerhoff3, Robert Parks2, William E Walkowicz4, Baptiste Aussedat4, Nelson R Wu2, Fangping Cai2, Yusuf Vohra4, Peter K Park4, Amanda Eaton5, Eden P Go6, Laura L Sutherland2, Richard M Scearce2, Dan H Barouch7, Ruijun Zhang2, Tarra Von Holle2, R Glenn Overman2, Kara Anasti2, Rogier W Sanders8, M Anthony Moody9, Thomas B Kepler10, Bette Korber11, Heather Desaire6, Sampa Santra12, Norman L Letvin12, Gary J Nabel13, David C Montefiori14, Georgia D Tomaras15, Hua-Xin Liao2, S Munir Alam2, Samuel J Danishefsky4, Barton F Haynes16.
Abstract
Induction of broadly neutralizing antibodies (bnAbs) that target HIV-1 envelope (Env) is a goal of HIV-1 vaccine development. A bnAb target is the Env third variable loop (V3)-glycan site. To determine whether immunization could induce antibodies to the V3-glycan bnAb binding site, we repetitively immunized macaques over a 4-year period with an Env expressing V3-high mannose glycans. Env immunizations elicited plasma antibodies that neutralized HIV-1 expressing only high-mannose glycans-a characteristic shared by early bnAb B cell lineage members. A rhesus recombinant monoclonal antibody from a vaccinated macaque bound to the V3-glycan site at the same amino acids as broadly neutralizing antibodies. A structure of the antibody bound to glycan revealed that the three variable heavy-chain complementarity-determining regions formed a cavity into which glycan could insert and neutralized multiple HIV-1 isolates with high-mannose glycans. Thus, HIV-1 Env vaccination induced mannose-dependent antibodies with characteristics of V3-glycan bnAb precursors.Entities:
Keywords: HIV; V3 glycan; glycan; long-term immunization; vaccination
Mesh:
Substances:
Year: 2017 PMID: 28249163 PMCID: PMC5408352 DOI: 10.1016/j.celrep.2017.02.003
Source DB: PubMed Journal: Cell Rep Impact factor: 9.423